A hypothesized role for dysregulated bradykinin signaling in COVID-19 respiratory complications.
FASEB J
; 34(6): 7265-7269, 2020 06.
Article
in English
| MEDLINE | ID: covidwho-155381
ABSTRACT
As of April 20, 2020, over time, the COVID-19 pandemic has resulted in 157 970 deaths out of 2 319 066 confirmed cases, at a Case Fatality Rate of ~6.8%. With the pandemic rapidly spreading, and health delivery systems being overwhelmed, it is imperative that safe and effective pharmacotherapeutic strategies are rapidly explored to improve survival. In this paper, we use established and emerging evidence to propose a testable hypothesis that, a vicious positive feedback loop of des-Arg(9)-bradykinin- and bradykinin-mediated inflammation â injury â inflammation, likely precipitates life threatening respiratory complications in COVID-19. Through our hypothesis, we make the prediction that the FDA-approved molecule, icatibant, might be able to interrupt this feedback loop and, thereby, improve the clinical outcomes. This hypothesis could lead to basic, translational, and clinical studies aimed at reducing COVID-19 morbidity and mortality.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Pneumonia, Viral
/
Receptors, Virus
/
Bradykinin
/
Coronavirus Infections
/
Peptidyl-Dipeptidase A
/
Bradykinin B2 Receptor Antagonists
/
Betacoronavirus
/
Models, Biological
Type of study:
Prognostic study
/
Randomized controlled trials
Topics:
Long Covid
Limits:
Humans
Language:
English
Journal:
FASEB J
Journal subject:
Biology
/
Physiology
Year:
2020
Document Type:
Article
Affiliation country:
Fj.202000967
Similar
MEDLINE
...
LILACS
LIS